Trial · NCT03139331
PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
NCT03139331, Phase 1, Completed, University of California, San Francisco
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma. Trials, record NCT03139331. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03139331
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
- NCT number
- NCT03139331
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 16 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Sarcoma, Refractory Sarcoma
- Interventions
- Pazopanib, Irinotecan, Temozolomide
- First posted
- 2017-05-03
- Last updated
- 2021-01-05
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum Tolerated Dose | 3 weeks | Maximum tolerated dose or recommended phase 2 dose of pazopanib administered in combination with irinotecan and temozolomide |
| Primary | Number of Patients with Dose-Limiting Toxicities (DLTs) Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 | 3 weeks | Toxicity will be graded using the CTCAE criteria, version 4.0. DLT will be defined as any of the events as defined per the protocol that are at least possibly, probably, or definitely attributable to the combination of pazopanib, irinotecan, and temozolomide. DLTs are generally grade 3 or greater in severity. Dose limiting hematological and non-hematological toxicities are defined differently, per the protocol. |
| Primary | Describing toxicities of PAZIT drug combination using NCI CTCAE Version 4.0 | 3 weeks | To describe any toxicities associated with the combination of pazopanib, irinotecan and temozolomide (PAZIT). |
| Secondary | Objective Response Rate Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 | From treatment initiation until disease progression, an average of about 6 months | The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. Tumor response will be assessed using RECIST version 1.1. |
| Secondary | Progression-Free Survival (PFS) Using RECIST Version 1.1 | From treatment initiation until disease progression, an average of about 6 months | PFS is defined as the duration of time from start of treatment to time of tumor progression. Tumor response will be assessed using RECIST version 1.1. |
| Secondary | Overall Survival (OS) | From treatment initiation until death, an average of about 1 year | OS is defined as the duration of time from start of treatment to time of death from any cause. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03139331
GET https://conductscience.org/api/trials/v1/NCT03139331/registered